Ceftriaxone is a new parenteral cephalosporin with broad-spectrum activity against gram-positive and gram-negative bacteria (1, 6) . The drug has enhanced stability against various 1-lactamase-producing bacteria (6) and a reportedly prolonged elimination half-life of 6 to 9 h (7-11), characteristics which make its use advantageous in a number of clinical settings (5) . Although the pharmacokinetics of ceftriaxone have been studied in volunteers and patients with normal renal function (7) (8) (9) (10) (11) , the drug has not been evaluated in patients with chronic renal failure. The prolonged elimination half-life of ceftriaxone would make it of considerable value in this population, which is prone to infection by gram-negative and gram-positive organisms. Thus, we wished to establish the pharmacokinetics of ceftriaxone in patients with severe renal impairment during dialysis and during an interdialysis period.
MATERIALS AND METHODS Subjects included eight patients (six males and two females) with end-stage renal disease who underwent hemodialysis three times per week at Columbia Presbyterian Medical Center (Table 1 ). All patients had an endogenous creatinine clearance of less than 5 ml/min at the time of study. No patient received another antibiotic during the study period, and no patient had a prior history of hypersensitivity to penicillins or cephalosporins. None of the patients had evidence of active liver disease or abnormal serum glutamic oxalacetic transaminase, glutamic pyruvic transaminase, or bilirubin at the time of the study. Written informed consent was obtained from all subjects before their participation in the study.
Each patient received 1 g of ceftriaxone disodium infused intravenously over 30 min on two separate occasions. The dose was administered simultaneously with the initiation of a 4-h hemodialysis procedure and again on an interdialysis day (between two hemodialysis procedures). A wash-out period of at least 3 days separated the two drug treatments. Dialysis was performed on a Cobe Century II dialysis machine, using a 1.3-m2 parallel plate cuprophane dialyzer, for 4 h.
Dialysate flow rates were kept constant at 500 ml/min, and blood flow rates were maintained at 250 to 300 ml/min. During dialysis, specimens were collected in heparinized tubes from arterial blood at the time of drug administration (zero time) and at 0.25, 0.5, 1, 2, and 4 h thereafter. Venous samples were collected at 1, 2, 4, 8, 12, and 24 h after the start of infusion. Dialysate samples were collected at the same time as arterial blood samples. During the interdialysis period, venous blood samples were collected from a peripheral vein at 0,0.25, 0.50, 1, 2, 3, 4, 8, 12 , and 24 h. Blood samples were centrifuged immediately, and the plasma so processed was stored at -70°C until assayed by high-pressure liquid chromatography. This method uses acetonitrile to yield a protein-free fraction of plasma that is assayed by reverse phase-ion pair highpressure liquid chromatography with UV detection at 280 nm. The assay is valid for ranges of 2 to 400 g±g/ml for plasma and 6 to 167 ,ug/ml for urine, using automated sample injection (7, 8) . Standards and patient samples were prepared in a similar manner. Ceftriaxone could be accurately measured in plasma at levels as low as 5 ,ug/ml and in dialysate at levels as low as 10 Fg/ml. The presence of the drug was detectable in dialysate at levels as low as 2 ,ug/ml.
Pharmacokinetic analysis, using the concentrations of ceftriaxone obtained, was performed to determine the terminal elimination rate constant (tQ12) by fitting plasma concentrations observed to a monoexponential equation by the nonlinear least-squares program, NONLIN (4), with the reciprocal of the plasma concentration as a weighting factor. The area under the curve (AUC) was calculated by the linear trapezoidal extrapolation method. Plasma clearance (Clp) was calculated from the dose divided by the AUC; and the 
RESULTS
Concentrations of ceftriaxone in arterial plasma and venous plasma during hemodialysis are shown in Table 2 . Dialysate levels were below the high-pressure liquid chromatography assay sensitivity for all specimens. The average venous plasma samples at 1, 2, and 4 h after dose (82, 65, and 53 ,ug/ml, respectively) corresponded closely with the arterial samples at the same times (80, 66, and 55 ,ug/ml, respectively). The AUCs for arterial and venous samples at 1 and 4 h also were similar. These data suggest negligible extraction of ceftriaxone during the hemodialysis procedure.
The concentrations of ceftriaxone observed in venous plasma during the interdialysis interval are shown in Table 3 . The average plasma concentration time profile as compared with that obtained in the hemodialysis interval is shown in Fig. 1 . The similarity of these profiles attests to negligible loss of drug during the hemodialysis period. Pharmacokinetic parameters determined for each patient are listed in Table 4 . These parameters could not be determined for patient no. 6 in either the dialysis study or the interdialysis study because plasma concentrations declined very slowly between 4 The present study shows that the t112 of ceftrithere was no significant difference between axone in patients with renal failue is longer, the these values during the dialysis and interdialysis Clp is smaller, and the Vd is larger than found in intervals. It should be noted that the pharmaco-previous studies of patients with normal renal function (7) (8) (9) (10) (11) . These results are similar to those of Wright and Wise in a study of a small sample of undialyzed patients with severe renal failure (12) . The larger Vd may relate to decreased plasma protein binding of the drug in patients with renal insufficiency (8, 11) . Assuming linear pharmacokinetics and utilizing the average pharmacokinetic parameters observed in the dialysis patients, multiple-dose administration of 1 g of ceftriaxone at 12-h intervals should produce an average steady-state concentration of 114 ,ug/ml. Thus, despite the observed decrease of up to twofold in elimination kinetics, this concentration is similar to that found in healthy subjects; thus, no dosage reduction is required for the majority of renal failure patients receiving ceftriaxone. A single 1-g dose administered every 24 h would be far in excess of the concentrations needed to inhibit most grampositive and gram-negative aerobic species. Indeed, a 1-g dose at the end of each dialysis treatment, i.e., every 2 to 3 days, would be quite adequate. Dialysis did not enhance the clearance of ceftriaxone, and supplemental doses of the drug do not appear necessary after hemodialysis. In comparison with other cephalosporin antibiotics studied by our group, there has been less removal of ceftriaxone by hemodialysis than of cefoxitin, cefotaxime, and moxalactam (Table  5 ). The doubling of the half-life of ceftriaxone from 8 to 14 h is much less than the increase of t1,2 of cefazolin from 2 to 40 h, cefoxitin to 21 h, and moxalactam to 19 h (Table 5 ). Of interest, two patients (no. 4 and 6) had substantially lower elimination rates of the drug (greater than a twofold decrease in elimination) than those observed for the remaining patients. Although all of the patients were clinically free of hepatic disease (see above), it is possible that subclinical hepatic dysfunction affected the biliary excretion process in these patients. During a clinical study of ceftriaxone (Scully and Neu, submitted for publication) we treated several renal failure patients who had a markedly prolonged t112 in spite of no apparent abnormality of liver function as determined by routine chemical tests. This individual variability suggests that plasma concentrations of the drug should be monitored during therapy in patients with renal insufficiency to avoid excessive drug accumulation.
